| Autor: |
Martínez, Esteban, Gatell, José, Morán, Yolanda, Aznar, Esther, Buira, Elisabet, Guelar, Ana, Mallolas, José, Soriano, Eladio |
| Zdroj: |
Clinical Infectious Diseases; 1998, Vol. 27 Issue 6, p1510-1513, 4p |
| Abstrakt: |
A high incidence of herpes zoster was noticed among patients with AIDS, shortly after addition of a protease inhibitor to their baseline treatment with nucleoside analogue reverse-transcriptase inhibitors. Within a median follow-up of 64 weeks (range, 34–103 weeks), 14 patients (7%) had a first episode or a recurrence of herpes zoster (6.2 episodes per 100 patient-years). No episodes of zoster were diagnosed before week 4. Twelve episodes (86%) occurred between weeks 4 and 16. The risk of zoster was independent of age, sex, type of protease inhibitor, and CD4+ lymphocyte count and viral load at baseline and month 1. A CD8+ lymphocyte proportion at baseline of >66% (hazard ratio [HR], 10.6; 95% confidence interval [CI], 3.4–33.1) and an increase in CD8+ lymphocyte proportion at month 1 of >5% (HR, 32; 95% CI, 8.1–126.4) were independently associated with the risk of herpes zoster. These data might be clinically useful for determining transient prophylaxis for those patients at high risk. [ABSTRACT FROM PUBLISHER] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
